Clinical Trial

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Name: A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma — clinical trial record (NCT07105059)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

Protocol Amendment History 1 change

minor Trial arms changed: 1 -> 3 2026-08-15

Trial Details

NCT Number	NCT07105059
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Bristol-Myers Squibb, Johnson & Johnson
Conditions	Multiple Myeloma
Enrollment	18 participants
Start Date	2025-08-08
Primary Completion	2028-08-08 (estimated)
Study Completion	2028-08-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-14